Published in Clin Cancer Res on January 10, 2013
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell (2016) 2.39
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer (2015) 1.53
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol (2014) 1.47
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst (2016) 1.40
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov (2014) 1.38
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal (2014) 1.37
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res (2014) 1.21
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 1.21
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20
The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol (2014) 1.20
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res (2013) 1.12
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09
Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.09
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res (2013) 1.08
Cancer vaccines. BMJ (2015) 1.07
Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.05
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
Isolation and molecular characterization of circulating melanoma cells. Cell Rep (2014) 1.02
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer (2015) 0.99
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98
MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology (2013) 0.96
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med (2014) 0.95
Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med (2015) 0.95
Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One (2014) 0.95
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res (2015) 0.95
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res (2013) 0.93
BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res (2014) 0.93
New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol (2013) 0.92
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res (2014) 0.92
Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med (2016) 0.90
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res (2014) 0.90
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology (2014) 0.89
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J (2014) 0.88
Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res (2014) 0.87
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer (2014) 0.87
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol (2016) 0.87
Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response. Cancer Immunol Res (2015) 0.87
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget (2014) 0.86
Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl) (2015) 0.86
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res (2015) 0.85
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol (2013) 0.85
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85
Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer (2015) 0.84
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology (2013) 0.83
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol (2014) 0.83
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol (2015) 0.83
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res (2015) 0.83
The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. Oncoimmunology (2014) 0.82
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol (2015) 0.82
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology (2016) 0.81
Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81
Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma? Nat Rev Clin Oncol (2015) 0.81
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. Front Oncol (2015) 0.80
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res (2015) 0.80
Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin Cancer Res (2013) 0.80
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in (V600E)BRAF melanoma cells. Lab Invest (2017) 0.80
Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. Eur J Cancer (2016) 0.79
Novel melanoma therapy. Exp Hematol Oncol (2016) 0.79
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.78
The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78
New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol (2015) 0.78
Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology (2015) 0.78
Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells. Melanoma Res (2015) 0.78
A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Mol Oncol (2016) 0.78
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology (2015) 0.78
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest (2017) 0.78
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology (2016) 0.78
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging (2017) 0.77
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology (2012) 1.43
Biological challenges of BRAF inhibitor therapy. Mol Oncol (2011) 1.08
Genetics of melanoma tumorigenesis. Br J Dermatol (2007) 1.07
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Identification of cells initiating human melanomas. Nature (2008) 8.28
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity (2007) 2.94
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65